TELA Bio, Inc.

TELA Bio, Inc. (TELA) priced its initial public offering on Nov 8, 2019 at $13.00 per share, raising $52M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $143.1M. Jefferies was lead-left underwriter, joined by Canaccord Genuity and Citizens JMP. Troutman Pepper advised the company and Latham & Watkins advised the underwriters.

TELA Bio, Inc. is a commercial-stage medical technology company that designs and markets reinforced tissue matrices for soft tissue reconstruction. Its products, used in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery, combine layers of biologic material with interwoven polymers and have been implanted in more than 6,500 patients.

Status

IPO

Ticker

TELA

Exchange

Nasdaq Global Market

Priced

Nov 8, 2019

IPO price

$13.00

Raised

$52M

Market cap at IPO price

$143.1M

First filed

Oct 15, 2019

Underwriters

Jefferies, Canaccord Genuity and Citizens JMP

Company counsel

Troutman Pepper

Underwriters' counsel

Latham & Watkins

Sector

Healthcare

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.